New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy
|
|
- Loreen Carpenter
- 6 years ago
- Views:
Transcription
1 New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant Professor Department of Dermatology Mount Sinai School of Medicine The Tisch Cancer Institute April 27, 2017 Melanoma Estimated that 76,380 people will be diagnosed with melanoma in the US in 2016 and approximately 10,130 people died from the disease Detection when early stage has greater than 90% cure rate. Lifetime risk is 1 in 34 for women, 1 in 53 for men Median age at diagnosis is 59 years old Incidence increasing rapidly 1
2 Staging Stage 5 yr survival 10 yr survival IA T1a N0 M0 T1 < 1 mm a ulc, b no IB T1b or T2a N0 M0 T mm IIA T2b or T3a N0 M0 T mm IIB T3b or T4a N0 M0 T4 >4mm IIC T4b N0 M0 53% 40% N1 1LN IIIA T1 4a N1 2a 78% 68% N2 2 3LN IIIB b a 59% 43% N2c satellite/intransit a b N3 >4LN N2c IIIC T1 4b N1 2b or N3 40% 24% Stage IV M1 15% 10% Lymph node Primary lesion a macroscopic a no ulceration b macroscopic b ulcerated Survival curves of 7,635 patients with metastatic melanomas at distant sites (stage IV) subgrouped by (A) the site of metastatic disease and (B) serum lactose dehydrogenase (LDH) levels. Charles M. Balch et al. JCO 2009;27: by American Society of Clinical Oncology 2
3 FDA Approved Therapies for Stage IV Melanoma (prior to 2011) Dacarbazine Interleukin 2 Targeted Immunotherapy Chemotherapy What About Immunotherapy? Rare spontaneous regressions Tumor infiltrating lymphocytes Activity HD IL2 in stage IV melanoma Activity Interferon Alpha in deep Stage II b/c and Stage III melanoma 3
4 Key Factors to Assess Immunotherapy EFFICACY TOXICITY HEALTH CARE EXPENDITURE The Balanced Immune system Activator Suppressor Activator Suppressor Activator Suppressor 4
5 Clinically Relevant Immune Checkpoints CTLA 4 PD 1 B7 CD28 Dendritic Cell MHC Ag TCR T cell T cell Tumor MHC Ag TCR B7 CTLA4 PD 1 PD L1 Ipilimumab Nivolumab Pembroluzimab Improved Survival with Ipilumimab in Patients with Metastatic Melanoma Ipilimumab N=137 Stage IV melanoma Not first Line Ipilimumab + gp100 N= 403 gp100 alone N= 136 Hodi et al. NEJM(2010): 363, pg
6 Kaplan Meier Curves for Overall Survival and Progression-free Survival in the Intention-to-Treat Population. Hodi et al., NEJM (2010) 363: Long Term Efficacy Ipilimumab Pooled Analysis OS Data 1861 patients 10 prospective and 2 retrospective ipilimumab melanoma studies Median OS 9.5 months Survival curve plateau at 21% beginning around year 3 with up to approximately 10 year f/u data IMPROVING THE TAIL END OF THE SURIVAL CURVE Schadendorf et al. (2015) JCO(33)
7 Clinically Relevant Immune Checkpoints CTLA 4 PD 1 B7 CD28 Dendritic Cell MHC Ag TCR T cell T cell Tumor MHC Ag TCR B7 CTLA4 PD 1 PD L1 Ipilimumab Nivolumab Pembroluzimab PD 1 Targeted Therapy Two Large Phase I Studies Study Phase Agent Dose Freq RR DR Med PFS Robert et al. Lancet (2014) 1 Topalian et al. JCO (2014) 2 I Pembrolizumab 2 mg/kg q 3wk 26% NR (12 42 week) 1yr OS 7.5 m 58% Prior ipi ibraf if mt I Nivolumab 3 mg/kg q 2 wk 41% 76 wk 9.7 m 62% 1 5 prior therapies 1. Robert et al. Lancet (2014) 384: Topalian et al. JCO (2014) 32:
8 Nivolumab versus DTIC Phase III Stage IV melanoma No BRAF mutation First line therapy OS primary endpoint 418 pts Placebo controlled 61% pts M1C disease Nivolumab 3mg/kg q 2 wk Or DTIC 1000 mg/m 2 q 3 weeks Robert et al. (2015) NEJM, vol 372, pg. 320 Nivolumab versus DTIC Phase III: RESULTS Nivolumab DTIC HR / p value 1 yr OS 72.9% 42.1% 0.42 / <0.001 Median PFS 5.1 m 2.2 m 0.43 / <0.001 RR 40% 13.9% <0.001 >gd3 toxicity 11.7% 17.6% Robert et al. (2015) NEJM, vol 372, pg
9 Pembrolizumab versus Ipilimumab Phase III Comparison 834 pts Stage IV melanoma No prior anti CTLA4 or anti PD 1 therapy Primary endpoints: PFS, OS Pembro 10 mg/kg q2wk Pembro 10 mg/kg q3wk Ipilimumab 3mg/kg q3wk x 4 doses Pembro q2wk Pembro q3wk Ipi P values 6m PFS 47% 46% 26.5% < m OS 74% 68% 58% RR 33.7% 32.9% 11.9% <0.001 >gd3 toxicity 13.3% 10.1% 19.9% Robert et al. (2015) NEJM, vol 372; pg Immune Checkpoint Modulation PD 1 inhibitors more efficacious than ipilimumab as initial immunotherapy Immune cell infiltration can lead to difficult assessing response purely by size of metastasis on imaging Durability of benefit 5 year survival nivolumab 34% While PD 1 inhibitor monotherapy a significant treatment advance still only effective in subset of patients 9
10 Clinically Relevant Immune Checkpoints CTLA 4 PD 1 B7 CD28 Dendritic Cell MHC Ag TCR T cell T cell Tumor MHC Ag TCR B7 CTLA4 PD 1 PD L1 Ipilimumab Nivolumab Pembroluzimab Combined Checkpoint Modulation Pembroluzimab Nivolumab Nivolumab plus Ipilimumab Hamid O et al. N Engl J Med 2013;369: Hamid et al. NEJM (2013) 369: Topalian et al. NEJM (2012) 366: Wolchok et al. NEJM (2013) 369:
11 CHECKMATE 067 Ipilimumab alone 3mg/kg q3wk x 4 doses +placebo Stage IV melanoma, 945 pts No prior systemic therapy for advanced disease Stratify: PD L1 expression BRAF mt vs wild type AJCC M stage Nivolumab 3 mg/kg q 2 wk +placebo Ipilimumab + Nivolumab ( 1mg/kg nivo q 3 wk + 3 mg/kg ipi q 3wk x 4 doses followed by 3mg/kg nivo q2 wk) Co primary endpoints: PFS and OS Only PFS data presented Larkin et al. (2015) NEJM, vol 373, pg. 23 Wolchock et al, 2016 ASCO Annual Meeting Abstract # Results N+I N alone I alone P value Median PFS 11.5 m 6.9 m 2.9 m < m PFS 49% 42% 18% 18m PFS 46% 39% 14% ORR 57.6% 43.7% 19% AE > gd 3 56% 19.8% 27% Median PFS PD L1 + PD L1 N+I NR 11.1 m N alone 22 m 5.3 m I alone 3.9 m 2.8 m Response Rate PD L1 + PD L1 N+I 72% 54% N alone 57% 41% I alone 21% 18% Larkin et al. (2015) NEJM, vol 373, pg. 23 Wolchock et al, 2016 ASCO Annual Meeting Abstract #
12 Key Factors to Assess Immunotherapy EFFICACY RR 12m PFS Survival Ipi 12% 18% 58% 12m 21% 3yr Nivo 40% 42% 73% 12m 34% 5 yr Pembro 33% 46% 6m 68% 12m Ipi + Nivo 58% 49% TOXICITY HEALTH CARE EXPENDITURE Toxicity Immune Mediated Toxicity Type Rash Colitis Hepatitis Nephritis Uveitis Endocrine Pneumonitis Neurologic Other organs TOXICITY MANAGEMENT DEPENDS ON TYPE AND SEVERITY OF TOXICITY 12
13 AE I Gd any Toxicity Risk % I Gd 3/4 N+I Gd any N+I Gd 3/4 N Gd any N Gd 3/4 P Gd any P Gd 3/4 Rash Colitis Diarrhea Hepatic (inc AST/ALT) Pneumonitis Hypothyroidism Hypophysitis Abbreviation I N P Name ipilimumab nivolumab pemrolizumab Adapted from Weber et al.(2016), The Oncologist, vol 21: Diarrhea/Colitis Grade Management Follow up I <4 stool/d above baseline Continue therapy Monitor closely II 4 6 BM/d above baseline or abd pain/blood stool III/IV >7 BM/d above baseline Severe colitis Hold Therapy Discontinue therapy, consider endoscopy, rule out infection, high dose steroids If persist >5 7 d then high dose steroids slow taper High dose steorids, slow taper Hepatitis Grade Management Follow up I AST/ALT >ULN to 3xULN T.Bili >ULN to 1.5xULN II AST/ALT > 3x to < 5xULN T.Bili >1.5x to <3xULN Continue therapy Hold treatment Recheck approx q3d Monitor closely Slow taper when gd 1 III/IV AST/ALT > 5xULN and/or T.Bili > 3xULN Discontinue therapy High dose steorids Consider GI consult Slow taper whe n gd 1 If not improve in 3 5 days mycophenolatemofetil 13
14 Endocrine Grade Management 1 Management 2 Asymptomatic TSH elevation Symptomatic Endocrinopathy Continue therapy If TSH <0.5xLLN or > 2xULN check FT4 and consider endocrinology consult Evaluate Endocrine function Delay therapy High dose steroids Initiate appropriate hormone therapy Endocrinology consult Adrenal Crisis Discontinue or delay therapy Rule out sepsis Stress dose steroids Hydration intravenously Consult endocrinology Monitor closely If improves then taper steroids over at least a month. Resume therapy For adrenal insufficiency continue steroids with mineralocorticoid component High dose steroids slow taper once improved. Usually need continue steroids lifelong. Adapted from Weber et al.(2016), The Oncologist, vol 21: Any Rx related AE Grade 3/4 Ipi 86% 27% Nivo 82% 16% Pembro 73% 10% Ipi + Nivo 96% 55% Key Factors to Assess Immunotherapy EFFICACY RR 12m PFS Survival Ipi 12% 18% 58% 12m 21% 3yr Nivo 40% 42% 73% 12m 34% 5 yr Pembro 33% 46% 6m 68% 12m Ipi + Nivo 58% 49% TOXICITY HEALTH CARE EXPENDITURE Robert et al. (2015) NEJM 372, ; Larkin et al. (2015) NEJM 373,
15 Cost Effectiveness of Treatment Benefits in terms of efficacy Through efficacy prevent morbidity of cancer and therefore reduce admission to hospital risk, procedures, interventions that have financial cost. Cost Effectiveness of Treatment Benefits Efficacy Through significant efficacy decrease need to manage morbidity related to progressing cancer (hospitalizations, procedures, subsequent systemic therapy or localized therapy such as surgery or RT) Costs Cost of managing treatment related toxicity Depending on degree efficacy are costs in patients who progress or do not tolerate treatment (other systemic therapy, localized approaches like surgery or RT, other procedures or hospitalizations) Financial costs of the treatment 15
16 The Financial cost of Immunotherapy Prices from the first quarter of 2015 show the average per milligram wholesale prices to be: Average per mg wholesale costs first quarter 2015 Immunotherapy Average Wholesale Price Per Milligram ($) FDA approved dose (# milligrams) Wholesale cost per dose ($) (100 kg person) Nivolumab mg/kg $8634 Pembrolizumab mg/kg $10,358 Ipilimumab mg/kg $47,238 Nivolumab Plus Ipilimumab N= 1 mg/kg I= 3mg/kg $50,116 Health Economic (2015), vol 8, pg 9 Estimated Cost Typical Patient Treated on CHECKMATE 067 $158,252 $103,220 $295,566 Approximate cost of 20% copay for I +N = $60,000 Ipilimumab alone 3mg/kg q3wk x 4 doses +placebo Nivolumab 3 mg/kg q 2 wk +placebo Ipilimumab + Nivolumab ( 1mg/kg nivo q 3 wk + 3 mg/kg ipi q 3wk x 4 doses followed by 3mg/kg nivo q2 wk) Health Economic (2015), vol 8, pg 9 Larkin et al. (2015) NEJM, vol 373, pg. 23 Wolchock et al, 2016 ASCO Annual Meeting Abstract #
17 Any Rx related AE TOXICITY Grade 3/4 Ipi 86% 27% Nivo 82% 16% Pembro 73% 10% Ipi + Nivo 96% 55% Key Factors to Assess Immunotherapy EFFICACY RR 12m PFS Survival Ipi 12% 18% 58% 12m 21% 3yr Nivo 40% 42% 73% 12m 34% 5 yr Pembro 33% 46% 6m 68% 12m Ipi + Nivo 58% 49% Estimated Cost Typical Patient ($) Ipi $158,252 Nivo $103,220 Ipi+ Nivo $295,566 HEALTH CARE EXPENDITURE Health Economic (2015), vol 8, pg 9; Robert et al. (2015) NEJM 372, ; Larkin et al. (2015) NEJM 373, 2331 Strategies to Decrease cost and Improve Efficacy Develop effective adjuvant treatment for earlier stage melanoma to prevent recurrence and the development of stage IV disease Identify biomarkers predictive of response 17
18 Melanoma Adjuvant High Dose Interferon Trials Trial name E1684(Kirkwood, Strawderman et al. 1996) E1690(Kirkwood, Ibrahim et al. 2000) E1694(Kirkwood, Ibrahim et al. 2001) Year Regimen HD IFN -2b 1 vs. obs HD IFN -2b vs. LD INF -2b 2 vs. obs HD IFN -2b vs. GMK vaccine 3 # patients enrolled Median follow up at initial reporting (yrs) Clinical Pathologic stage (% pts) T 4 cn 0 T 1-4 pn 1 cn 0 T 1-4 pn 0 cn 1 T 1-4 pn 0 cn 1 recurrent RFS benefit + p 5 = (.0023) OS benefit + p= (.0237) Median RFS (obs vs. HD IFN ) yrs Median OS (obs vs. HD IFN ) yrs (only HD INF ) HR 6 =1.28 p=(.05) HR=1.47 p=(.0007) - + HR=1.28 p=(.035) 1 vs vs vs. NR vs vs. 5.1 NR Melanoma Adjuvant High Dose Interferon Trials Trial name Median follow up at latest reporting (yrs) RFS benefit OS benefit E1684(Kirkwood, Strawderman et al. 1996) E1690(Kirkwood, Ibrahim et al. 2000) E1694(Kirkwood, Ibrahim et al. 2001) HR=1.38 p=(.02) - HR=1.22 p=(.18) - HR=1.24 p=(.09) + HR=1.33 p=(.006) - + HR=1.32 p=(.04) 1) HD IFN -2b 20MIU IV 5 days per week x 4 weeks followed by 10 MIU SQ TIW x 48 weeks 2) LD INF -2b 3 MIU TIW SQ x 2 years 3) GMK vaccine 1mL SQ on days 1, 8, 15, 22 then every 12 weeks 4) T 4c N 0 Primary >4 mm depth No LN involvement detected T 1-4 pn 1 cn 0 LN involvement determined on pathology T 1-4 pn 0 cn 1 LN determined on clinical evaluation at time of primary diagnosis T 1-4 pn 0 cn 1 recurrent LN determined on clinical evaluation after primary diagnosis 5) P value one sided 6) Hazard ratio 7) Not reached 18
19 Ipilimumab adjuvant therapy Resected stage III melanoma (to regional lymph nodes) N=475 Ipilimumab 10 mg/kg q3k x4 doses followed by q3month for up to 3 years N=476 Placebo Characteristic Ipilimumab Placebo Median Age 51 yr 52 yr IIIa 20.6% 20.6% IIIb 38.3% 38.2% IIIc 41.1% 41.2% LN macroscopic 55.8% 59.5% Eggermont et al. (2016) NEJM vol 375 p Results Median f/u 5.3yr Ipilimumab Placebo Median RFS 27.6m 17.1m HR 0.76, p< yr RFS 40.8% 30.3% Overall survival 5 yr 65.4% 54.4% HR 0.72 p=0.001 Median Distant Metastasis Free Survival Distant Metastasis Free Survival 5 yr 48.3 m 27.5 m HR 0.76 p= % 38.9% Post protocol treatment if recurred anti PD1 Distant Metastasis Free Survival BRAF inhibitor 24/264 (9.1%) 30/323 (9.3%) 63/264 (23.9%) 88/323 (27.2%) Pt recruitment
20 Toxicity Event Ipilimumab % Placebo % Any immune related 90.4% 39.7% AE Any immune related AE gd3 35.9% 2.5% Any immune related AE gd4 5.7% 0.2% Gd5 immune related AE >gd3 diarrhea/colitis >gd3 hepatic >gd3 endocrine 1.1% (5/471) 0% 16.6% 0.6% 8.1% 7.2% 0.2% 0.2% >gd3 dermatologic 4.2% 0% Financial cost Ipilimumab $ average per mg wholesale cost (1 st quarter 2015) Dose = 10 mg/kg Cost $ /kg/dose For 100 kg person = $157,460/dose Dose every 3 weeks x 4 = $629,840 20
21 Talimogene Laherparepvec (TVEC) Intratumorally delivered Oncolytic immunotherapy Herpes virus that selectively replicates in solid tumors Deletion of HSV 1 viral genes encoding ICP34.5, providing for tumor selective replication, and ICP47 which increases US11 expression enhancing virus growth and tumor cell replication. Gene for GM CSF has been inserted into the viral genome Duel Mechanism of Action: 1. Direct oncolytic effect by viral replication in tumor leading to tumor cell lysis 2. Anti tumor response in setting GM CSF expression in tumor microenvirnoment leading to systemic immune response Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, secondgeneration oncolytic herpesvirus in patients with unresectable metastatic melanoma. 50 pts IIIc 10 M1a 16 M1b 4 M1c 20 Senzer N et al. JCO 2009;27:
22 Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, secondgeneration oncolytic herpesvirus in patients with unresectable metastatic melanoma. 50 pts IIIc 10 M1a 16 M1b 4 M1c 20 Senzer N et al. JCO 2009;27: Combination Therapy Optimize Efficacy while minimize toxicity Combinations of checkpoint inhibitors Combination checkpoint inhibitors with TVEC Combination checkpoint inhibitors with tumor microenvironment modulators (anti vascular agents, IDO inhibitors) Combination checkpoint inhibitors and targeted therapy 22
23 Biomarkers of Immunotherapy Efficacy Blood Neutrophil/lymphocyte ratio Effector to Suppressor T cells CTLA 4 polymorphisms Tumor PD L1 expression TILs Mutation burden Easily obtained with minimal risk to patient Ideally Pretreatment Optimize treatment planning Limit toxicity risk Improve healthcare expenditure Patient Population Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez Navarro J, Liang JQ, Bulanhagui CA: Phase II trial of tremelimumab (CP 675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010, 16(3): Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G et al: Phase III randomized clinical trial comparing tremelimumab with standard of care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013, 31(5):
24 16 Gene Pre treatment Gene Signature From Blood Sample Predicts For Response and Survival The sensitivity, specificity, negative predictive value, and area under the curve of the pre treatment 16 gene signature predicting response in the training data set and both response and survival in the test dataset. 16 Gene Pre Treatment Response Predictive Model Training Data. X Axis is the correlated component score and Y axis is the composite response prediction score. Red squares (responders) and blue circles (non responders). Friedlander P, et al, (2016) SITC abstract #158, Poster presentation titled: Consistent blood based gene expression correlates with change in CTLA4 in two large independent clinical studies of advanced melanoma patients treated with tremelimumab FDA Approved Therapies for Stage IV Melanoma Dacarbazine Interleukin 2 Ipilimumab Targeted Vemurafenib Dabrafenib Trametinib Dabrafenib + Trametinib Pembroluzimab Nivolumab Immunotherapy Chemotherapy 24
25 Conclusions Dramatic advances in managing stage IV melanoma through immunomodulation Need biomarkers for efficacy and toxicity Overcome molecular and immune resistance mechanisms Goal to optimize efficacy and quality of life while minimizing toxicity and health care expenditure 25
Best Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationEvolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures
Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced Melanoma
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationReview of immunotherapy in melanoma
Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationUniversity of California Los Angeles, Los Angeles, CA; 2. Department of Dermatology, University of Kiel, Kiel, Germany;
Final Efficacy Results of A3671009, a Phase III Study of Tremelimumab vs Chemotherapy (Dacarbazine or Temozolomide) in First-line Patients With Unresectable Melanoma Antoni Ribas, 1 Axel Hauschild, 2 Richard
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationMelanoma in Focus: Update on Novel Therapy, Emerging Agents, and Optimizing Patient Care Presentation 1
Presentation 1 The following is a transcript from a web-based CME -certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational
More informationIMMUNOTARGET THERAPY: ASPETTI GENERALI
IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,
More informationWho is the Ideal Candidate for PEG Intron?
Who is the Ideal Candidate for PEG Intron? Sanjiv S. Agarwala, MD Chief, Oncology & Hematology St. Luke s Cancer Center Professor, Temple University School of Medicine Philadelphia, PA, USA Overview Introduction
More informationToxicity from Checkpoint Inhibitors. James Larkin FRCP PhD
Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures Research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): BMS, Eisai, GSK, MSD, Novartis, Pfizer, Roche/Genentech
More informationPembrolizumab: First in Class for Treatment of Metastatic Melanoma
Section Editors: Christopher J. Campen and Beth Eaby-Sandy Pembrolizumab: First in Class for Treatment of Metastatic Melanoma CARRIE BARNHART, PharmD From Billings Clinic Cancer Center, Billings, Montana
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationAdjuvant Therapy of High Risk Melanoma
Adjuvant Therapy of High Risk Melanoma William Sharfman, MD, FACP Associate Professor of Oncology and Dermatology Johns Hopkins University School of Medicine July 5, 2012 Adjuvant options for Stage IIB/C
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationTalimogene Laherparepvec (T-VEC) at the SCCA: an update
Talimogene Laherparepvec (T-VEC) at the SCCA: an update Jennifer M. Gardner, MD Assistant Professor, Division of Dermatology University of Washington jen1110@uw.edu Northwest Melanoma Symposium: Science
More informationA Case Study: Ipilimumab in Pre-treated Metastatic Melanoma
A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma Tai-Tsang Chen, PhD Global Biometric Sciences, Bristol-Myers Squibb EFSPI Statistical Meeting on Evidence Synthesis Brussels, Belgium November
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More information2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationMetastasectomy for Melanoma What s the Evidence and When Do We Stop?
Metastasectomy for Melanoma What s the Evidence and When Do We Stop? Vernon K. Sondak, M D Chair, Moffitt Cancer Center Tampa, Florida Focus on Melanoma London, UK October 15, 2013 Disclosures Dr. Sondak
More informationHuman leukocyte antigen (HLA) system
Is HLA a determinant of prognosis or therapeutic response to cytokines, IFN and anti-ctla4 blocking antibodies in melanoma? Helen Gogas, M.D. Ass. Professor in Medical Oncology 1st Department of Medicine,
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationMELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone
MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationNew Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors
New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors Farah Brasfield, MD Chair, Regional Chiefs of Oncology Kaiser Permanente Jennifer Chang, PharmD, MPH Supervisor, Drug Information Services
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationManaging immune related toxicity. Karijn Suijkerbuijk May 27 th 2017
Managing immune related toxicity Karijn Suijkerbuijk May 27 th 2017 Disclosures Advisory role: BMS, Merck Travel support: Amgen, Novartis, Roche Whybother? Patients are dying from toxicity Eggermont ipilimumab
More informationUpdate on Melanoma Treatment. Tara C Mitchell, MD
Update on Melanoma Treatment Tara C Mitchell, MD Overview Immune therapy update Targeted therapy update New concepts in treating melanoma What is the immune system? A complex network of protective cells
More informationSingle Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV melanoma
Single Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment:
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationAn update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.
Sullivan et al. Journal for ImmunoTherapy of Cancer (2018) 6:44 https://doi.org/10.1186/s40425-018-0362-6 POSITION ARTICLE AND GUIDELINES Open Access An update on the Society for Immunotherapy of Cancer
More informationMelanoma: The poster child for immunotherapy Jason J. Luke, M.D., F.A.C.P.
Melanoma: The poster child for immunotherapy Jason J. Luke, M.D., F.A.C.P. SITC Immunotherapy CME - June 23 rd, 2016 Disclosures Consultancy: Amgen Array Research Grant Support to Institution: Bristol
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationBlack is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)
Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationMelanoma Immunotherapy. Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management
Melanoma Immunotherapy Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management Mike Buljan, NP UCSF Medical Center Melanoma Oncology Disclosures None Only FDA-approved
More informationSurgical Treatment of Melanoma Across the Disease Spectrum:
AOCD Annual Fall Meeting October 28 th, 2017 New Orleans, Louisiana Surgical Treatment of Melanoma Across the Disease Spectrum: Standards of Care and Evolving Paradigms Merrick Ross, M.D. Professor of
More informationMANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS
MANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS John B.A.G. Haanen MD PhD CONTENT OF THIS PRESENTATION General aspects of immune related adverse events related to immune checkpoint
More informationCutaneous melanoma: new developments for 2018
Cutaneous melanoma: new developments for 2018 and beyond KIM MARGOLIN, M.D., FASCO CITY OF HOPE MEDICAL ONCOLOGY CORONADO, CALIFORNIA SEPTEMBER 20, 2018 DISCLOSURE Consultant for ImaginAb, Nektar Therapeutics,
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationNCCN Guidelines for Cutaneous Melanoma V Meeting on 06/20/18
ME-1, ME-3, ME-B Submission from Castle Biosciences, Inc (05/30/18) to consider inclusion of the DecisionDx-Melanoma test in the guidelines as a prognostic test that provides stratification according to
More informationMelanoma: Early Detection and Therapeutic Progress
Melanoma: Early Detection and Therapeutic Progress David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Surgery Thanks to my collaborators, mentors and patients May 19, 2017 Disclosures:
More informationMelanoma- Fighting the Dark Side
Melanoma- Fighting the Dark Side Anna C. Pavlick, BSN, MSc, DO, MBA Professor of Medicine and Dermatology Director, NYU Melanoma Program Director, NYU Clinical Trials Office NYU Perlmutter Cancer Center
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationImmunotherapy Experience in Melanoma Integrating IO into Clinical Practice Sanjiv S. Agarwala, MD
Immunotherapy Experience in Melanoma Integrating IO into Clinical Practice Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer
More informationOPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS
OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS Alberto Fusi Charité Comprehensive Cancer Centre Berlin, Germany 1 Immune check point blockade with CTLA-4, anti-pd-1
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationImmune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes
Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Geoffrey T. Gibney, MD Associate Professor Co-leader, Melanoma Disease Group Lombardi Comprehensive Cancer Center
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationMarshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011
Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011 Most common form of cancer in adults ages 25-29 3-5% of skin cancers but 65-75% of deaths Most common metastasis to small
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationUnmet Need Mucosal and Uveal Melanoma
Unmet Need Mucosal and Uveal Melanoma Matteo Carlino Crown Princess Mary Cancer Centre Westmead and Blacktown Hospitals Melanoma Institute Australia The University of Sydney. Cutaneous Overall Survival
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationHow can we reduce the mortality from melanoma in Australia?
How can we reduce the mortality from melanoma in Australia? Professor Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia University of Melbourne, Parkville, Australia What is melanoma?
More information